Big Pharma Giants Continue Q4 Earnings Besting Wall Street Expectations

Pfizer and GlaxoSmithKline (GSK) are the latest Big Pharma giants to report Wall Street-besting earnings for the fourth quarter of 2023. Both companies topped analysts’ expectations after hiking prices on blockbuster products throughout the year. One key area for both companies was their recently launched respiratory syncytial virus (RSV) vaccines, which brought in massive profits for both firms. Both companies targeted their RSV vaccines with price increases even before they were widely available to patients.



The strong earnings come as both drug makers have launched significant price hikes in recent years – including at the start of this year. Both companies have also engaged in a scheme to increase prices “in lockstep” on their new RSV vaccine products.



Pfizer & GlaxoSmithKline’s RSV Vaccine Price Hike Scheme

Read more on Q4 earnings from Johnson & Johnson HERE.

Read more on Pfizer and GSK’s RSV vaccine price hiking scheme HERE.

And stay tuned as we continue to monitor earnings calls from Big Pharma for Q4 of 2023 over the next few weeks.

Learn more about solutions to lower prescription drug prices and hold Big Pharma accountable HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.